What are the implications of changing treatment delivery models for patients with inflammatory bowel disease: a discussion paper

被引:14
|
作者
Mikocka-Walus, Antonina A. [1 ,3 ]
Andrews, Jane M. [4 ,5 ]
von Kaenel, Roland [2 ]
Moser, Gabriele [6 ]
机构
[1] Brocher Fdn, Geneva, Switzerland
[2] Univ Hosp Bern, Inselspital, Dept Gen Internal Med, CH-3010 Bern, Switzerland
[3] Univ S Australia, Sch Nursing & Midwifery, Adelaide, SA 5001, Australia
[4] Royal Adelaide Hosp, Dept Gastroenterol & Hepatol, IBD Serv, Adelaide, SA 5000, Australia
[5] Univ Adelaide, Sch Med, Adelaide, SA, Australia
[6] Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, Vienna, Austria
关键词
biopsychosocial; inflammatory bowel disease; integrated model of care; treatment delivery; RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE; INTEGRATED CARE; ULCERATIVE-COLITIS; MANAGEMENT; ANXIETY; IBD; ANTIDEPRESSANTS; THERAPY; PERSPECTIVES;
D O I
10.1097/MEG.0b013e32835c07b4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
An integrated model of care has been used effectively to manage chronic diseases; however, there is limited, yet encouraging evidence on its introduction in the management of inflammatory bowel disease (IBD), a chronic gastrointestinal condition. Here, the rationale for and implications of introducing an integrated model of care for patients with IBD are discussed, with a particular focus on psychology input, patient-centred care, efficiency as perceived by patients and doctors, financial implications and the possible means of model introduction. This is a discussion paper on the integrated model of care for IBD against a background of what has been learned from an integrated model of care established in other chronic conditions. Although limited, the emerging data on an integrated model of care in IBD are encouraging with respect to patient outcomes and savings in healthcare costs. In other conditions, the model has been well received by both patients and practitioners, although the loss of autonomy by doctors is listed among its drawbacks. The cost-effectiveness data are now sufficiently convincing to recommend the model's acceptance in principle. The model should be promoted at the policy level rather than by individual practitioners to facilitate equal access for patients with IBD on a larger scale than currently. Eur J Gastroenterol Hepatol 25:393-398 (C) 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins. European Journal of Gastroenterology & Hepatology 2013, 25:393-398
引用
收藏
页码:393 / 398
页数:6
相关论文
共 50 条
  • [1] Integrated models of care in managing inflammatory bowel disease: A discussion
    Mikocka-Walus, Antonina A.
    Andrews, Jane M.
    Bernstein, Charles N.
    Graff, Lesley A.
    Walker, John R.
    Spinelli, Antonino
    Danese, Silvio
    van der Woude, C. Janneke
    Goodhand, James
    Rampton, David
    Moser, Gabriele
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (08) : 1582 - 1587
  • [2] Implications of the changing epidemiology of inflammatory bowel disease in a changing world
    Agrawal, Manasi
    Jess, Tine
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2022, 10 (10) : 1113 - 1120
  • [3] What is the evidence for the use of probiotics in the treatment of inflammatory bowel disease?
    Cary, Virginia A.
    Boullata, Joseph
    JOURNAL OF CLINICAL NURSING, 2010, 19 (7-8) : 904 - 916
  • [4] White Paper AGA: The Impact of Mental and Psychosocial Factors on the Care of Patients With Inflammatory Bowel Disease
    Szigethy, Eva M.
    Allen, John I.
    Reiss, Marci
    Cohen, Wendy
    Perera, Lilani P.
    Brillstein, Lili
    Cross, Raymond K.
    Schwartz, David A.
    Kosinski, Lawrence R.
    Colton, Joshua B.
    LaRusso, Elizabeth
    Atreja, Ashish
    Regueiro, Miguel D.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (07) : 986 - 997
  • [5] Efficacy of duloxetine add on in treatment of inflammatory bowel disease patients: A double-blind controlled study
    Daghaghzadeh, Hamed
    Naji, Fateme
    Afshar, Hamid
    Sharbafchi, Mohammad Reza
    Feizi, Awat
    Maroufi, Mohsen
    Tabatabaeeyan, Mahshid
    Adibi, Peyman
    Tavakoli, Hamid
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2015, 20 (06): : 595 - 601
  • [6] Pediatric inflammatory bowel disease and depression: treatment implications
    Keethy, Divya
    Mrakotsky, Christine
    Szigethy, Eva
    CURRENT OPINION IN PEDIATRICS, 2014, 26 (05) : 561 - 567
  • [7] Quality of Care in Patients With Inflammatory Bowel Disease
    Jackson, Belinda D.
    De Cruz, Peter
    INFLAMMATORY BOWEL DISEASES, 2019, 25 (03) : 479 - 489
  • [8] Nanoparticle methotrexate delivery system for the treatment of paediatric patients with inflammatory bowel disease.
    Liu, Gang
    Li, Dun-Chen
    Li, Ping-Ping
    Li, Ran-Ran
    Chen, Shu-Ying
    BIOMEDICAL RESEARCH-INDIA, 2017, 28 (08): : 3328 - 3335
  • [9] Psychological treatment for patients with inflammatory bowel disease
    Jose Leiva, Maria
    REVISTA MEDICA CLINICA LAS CONDES, 2019, 30 (05): : 365 - 371
  • [10] Adherence to treatment in patients with inflammatory bowel disease
    Andreev, K. A.
    Gorbenko, A., V
    Skirdenko, Yu. P.
    Nikolaev, N. A.
    Livzan, M. A.
    Bikbavova, G. R.
    Fedorin, M. M.
    BYULLETEN SIBIRSKOY MEDITSINY, 2021, 20 (03): : 120 - 128